SIBN · XBRL financial data

SI-BONE financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SIBN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	73,387	90,152	106,409	138,886	167,178	200,925
Cost of goods and services sold	8,902	10,428	15,705	29,466	35,057	41,046
Gross profit	64,485	79,724	90,704	109,420	132,121	159,879
Research and development	9,459	12,441	13,627	15,028	16,560	17,448
General and administrative	19,803	25,069	28,960	31,069	33,755	40,537
Total operating expenses	103,052	131,394	150,313	156,351	167,369	182,209
Operating income (loss)	(38,567)	(51,670)	(59,609)	(46,931)	(35,248)	(22,330)
Interest income	1,097	186	1,304	6,916	7,848	6,074
Interest expense	6,101	5,365	2,819	3,462	3,440	2,628
Other income (expense)	(126)	277	(132)	141	(73)	(20)
Income tax expense (benefit)	—	0	0	0	0	0
Net income (loss)	(43,697)	(56,572)	(61,256)	(43,336)	(30,913)	(18,904)
Earnings per share, basic USD per share	(1.50)	(1.71)	(1.79)	(1.13)	(0.75)	(0.44)
Earnings per share, diluted USD per share	(1.50)	(1.71)	(1.79)	(1.13)	(0.75)	(0.44)
Weighted average shares, basic thousands of shares	29,059	33,146	34,202	38,427	41,467	42,960
Weighted average shares, diluted thousands of shares	29,059	33,146	34,202	38,427	41,467	42,960

Fiscal years (SIBN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	53,581	63,419	20,717	33,271	34,948	42,240
Marketable securities	142,851	83,560	76,573	—	—	—
Marketable securities, non-current	0	—	—	—	—	—
Accounts receivable	13,611	14,246	20,674	21,953	27,459	29,915
Inventory	5,633	11,498	17,282	20,249	27,074	33,897
Prepaid and other current assets	2,565	3,143	2,365	3,173	3,204	4,480
Total current assets	218,241	175,866	137,611	211,394	207,779	216,115
Property and equipment, net	4,527	8,992	15,564	16,000	20,374	21,298
Right-of-use asset	0	5,248	4,002	2,706	1,984	1,087
Total assets	223,142	190,506	157,552	230,425	230,437	238,555
Accounts payable	3,271	3,198	6,279	4,588	6,488	4,631
Accrued liabilities	10,199	12,353	13,511	17,452	19,492	19,704
Current portion of long-term debt	0	0	—	—	—	—
Total current liabilities	13,470	16,890	21,178	23,456	27,132	25,279
Long-term debt	39,455	34,973	35,171	36,065	35,452	35,569
Lease liability, non-current	0	4,166	2,871	1,511	879	175
Total liabilities	53,779	56,086	59,250	61,050	63,473	61,023
Accumulated deficit	(239,277)	(295,849)	(357,105)	(400,441)	(431,354)	(450,258)
Total stockholders' equity	169,363	134,420	98,302	169,375	166,964	177,532
Total liabilities and equity	223,142	190,506	157,552	230,425	230,437	238,555
Common shares outstanding (cover page) thousands of shares	32,728	33,841	34,986	41,065	42,453	44,165

Fiscal years (SIBN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(43,697)	(56,572)	(61,256)	(43,336)	(30,913)	(18,904)
Stock-based compensation	11,927	16,866	23,061	24,057	25,869	25,524
Depreciation and amortization	1,130	2,086	3,452	5,428	4,379	5,770
Net cash from operating activities	(30,662)	(39,533)	(41,655)	(18,713)	(12,425)	(675)
Purchases of property and equipment	2,561	6,389	9,507	7,799	10,497	8,414
Net cash from investing activities	(62,916)	51,580	(2,815)	(59,798)	12,623	4,160
Proceeds from issuing common stock	134,616	0	0	83,671	0	0
Proceeds from long-term debt	45,297	35,000	0	36,000	36,000	0
Repayments of long-term debt	45,297	41,000	0	35,275	36,000	0
Net cash from financing activities	136,401	(1,711)	2,197	90,933	1,958	3,376
Net change in cash	43,146	9,838	(42,702)	12,554	1,677	7,292

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
SI-BONE	35,311	55,704	5,940*	45.1M	—	Q3 FY26 10-QSep 30, 2026
Biolife Solutions	23,997	not reported	6,348*	48.9M	—	Q2 FY26 10-QJun 30, 2026
Embecta	214,700	271,700	41,800*	56.7M	—	Q3 FY26 10-QJun 30, 2026
Mimedx Group	120,791	62,283	3,919*	145.9M	—	Q3 FY26 10-QSep 30, 2026
Heartflow	34,362	64,082	(8,577)*	87.0M	19.0 quarters	Q2 FY26 10-QJun 30, 2026
Integra Lifesciences Holdings	252,261	411,182	95,977*	77.8M	—	Q3 FY26 10-QSep 30, 2026
Establishment Labs Holdings	71,157	67,542	(16,602)*	29.8M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
NovoCure	96,734	193,399	22,667	116.9M	—	Q3 FY26 10-QSep 30, 2026
Beta Bionics	81,551	35,505	(12,287)*	54.4M	13.0 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.